Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I8/505

[1] 万学红,卢雪峰. 诊断学[M]. 8版，北京: 人民卫生出版社, 2013：254-255.
[2] 陈伟, 李永胜. 碳青霉烯致继发性血小板增多症1例报道及不良反应文献复习[J]. 中国现代医学杂志, 2015, 25(17): 107-108.
[3] 李永胜, 陈伟, 周璇, 等. 比阿培南致继发性血小板增多症病例报告并文献复习[J]. 内科急危重症杂志, 2014, 20(6): 394-395.
[4] 肖兰, 杨明莉. 亚胺培南-西司他丁钠致继发性血小板增多症[J]. 药物不良反应杂志, 2009, 11(6): 443-444.
[5] 潘鹏玉, 甄健存. 美罗培南在国内外临床指南中的推荐[J]. 临床合理用药杂志, 2015,8(23): 180-181.
[6] Guan D X, Feng Z Z, Feng X P, et al. Analysis of Meropeneminduced Adverse Drug Reactions[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2009,9(5):397-398.
[7] Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem[J]. Drug Saf, 2007, 30(8): 657-668.
[8] Wakisaka K, Tant S, Ishibashi K, et al. Results of a post-marketing surveillance of meropenem for febrile neutropenia[J]. Japanese Journal of Antibiotics, 2015, 68(4): 205-224.
[9] 张丽琼, 杨炳所, 盛长城. 1例美罗培南导致癫痫样反应的病例分析[J]. 中国执业药师, 2016, 13(11): 53-56.
[10] 计倩, 张忠元. 美罗培南致药物性肝损伤2例[J]. 医药导报, 2016, 35(1): 102-103.
[11] 陈旭照. 以循证药学指导美罗培南治疗重症感染的临床应用 [J]. 中国药物警戒, 2013, 8(10): 505-507.
[12] Hsu H L, Lu C Y, Tseng H Y, et al. Empirical monotherapy with meropenem in serious bacterial infections in children[J]. J MicrobiolImmunol Infect, 2001, 34(4): 275-280.
[13] Khan M U, Yousuf R I, Shoaib M H. Drug utilization evaluation of meropenem and correlation of side effects with renal status of patients in a teaching based hospital[J]. Pak J Pharm Sci, 2014, 27(5): 1503-1508.
[14] Zhou Q T, He B, Shen N, et al. Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract[J]. Drugs Aging, 2017, 34(2): 115-121.
[15] Usman M, Frey O R, Hempel G. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function[J]. Eur J ClinPharmacol, 2017, 73(3): 333-342.
[16] Raymond S, Bourdelin M, Becker M, et al. Antibiotics in elderly patients: Impact of clinical practice evaluation[J]. Medecine et maladies infectieuses, 2011, 41(6): 330-335.
[17] 杨长春,韩盈,白,等.老年患者感染特点及抗菌药物的合理应用[J].中华医院感染学杂志,2010,20(14):2125-2126.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.